A review on quality by design

Vrushali Mogal, Jaydeep Dusane, Pankaj Borase, Priya Thakare, Sanjay J. Khirsagar


Quality by Design (QbD) refers to a new approach to product development that could increase efficiencies, provide regulatory relief and flexibility, and offer important business benefits throughout the product life cycle. It supports both industry and FDA to move towards a more scientific, risk based, holistic and proactive approach to pharmaceutical development. During designing and development of a product in QbD, a company needs to define desire product performance profile [Target Product Profile (TPP), Target Product Quality Profile (TPQP)] and identify critical quality attributed (CQA). The company then designs the product formulation and processes to meet the product attributes. This leads to understanding the impact of raw materials [Critical Material Attributes (CMA)], on the CQAs and identifies and control sources of variability. This systematic approach to product development and manufacturing has received a great deal from the traditional approach, which was extremely empirical. QbD is necessary in regulatory requirement, and to implement new concepts such as design space, International Conference on Harmonization‟s guidelines i.e. Q8 pharmaceutical development, Q9 quality risk management, and FDAs process analytical technology (PAT).


Quality by design, Target product profile, Target product quality profile, Critical quality attributes, Process analytical technology

Full Text:



Gawade A, Chemate S, Kuchekar A. Pharmaceutical Quality by Design: A New Approach in Product Development. Research and Reviews: Journal of Pharmacy and Pharmaceutical Sciences. 2013;2:5-11.

Juran JM. On quality by design The new steps for planning quality into goods and services Newyork free press; 1992: 1-2.

Food and Drug Administration. Final Report on Pharmaceutical cGMPs for the 21st Century - A Risk Based Approach. http://www.fda.gov/ cder/ gmp/ gmp 2004/ GMP_ final report 2004.htm. Accessed 10 March 2016.

Jain S. Quality by Design (QbD): A Comprensive understanding of implementation and challenges in pharmaceutical development. Int J of Pharm Pharma Sci. 2014;6:29-35.

US Food and Drug Administration. Guidance for industry: Q8(R2) pharmaceutical development. US Department of Health and Human Service, FDA, Rockville, MD; 2009.

Looby M, Ibarra N, Pierce JJ, Buckley K, O'Donovan E, Heenan M, et al. Application of quality by design principles to the development and technology transfer of a major process improvement for the manufacture of a recombinant protein. Biotechnology Progress. 2011;27(6):1718-29.

Nadpara NP, Thumar RV, Kalola VN, Patel PB. Quality by Design : A complete review. Int J Pharm Sci Rev Res. 2012;2:20-8.

Chang RK, Raw A, Lionberger R, Yu L. Generic development of topical dermatologic products, part II: quality by design for topical semisolid products. AAPS J. 2013;15(3):674-83.

McConnell J, McGarvey B, Nunnally B. Quality risk management and variability reduction. Journal of Validation Technology. 2011:12-6.

Mollah H, Baseman H, Long M. Risk Management Applications in Pharmaceutical and Biopharmaceutical Manufacturing: Wiley; 2013.

White E. Risk Management for Aseptic Processing. Journal of Validation Technology. 2009;15(2):25-33.

Gad SC. Handbook of Pharmaceutical Biotechnology. Gad SC, editor: Wiley; 2007.

Keizer JA, Vos J-P, Halman JIM. Risks in new product development: devising a reference tool. R&D Management. 2005;35(3):297-309.

Ranga S, Jaimini M, Sharma SK, Chauhan BS, Kumar A. A review on design of experiment. International Journal of Research and Reviews in Pharmacy and Applied science. 2013;3(6):867-82.

Monica RP, Rao P. Preparation and evaluation of immediate release tablets of meroclopramide HCL using Simplex Centruoid Mixture Design. International journals of pharma tech research. 2010;2:1105.

Q8 Pharmaceutical Development – FDA guidance

Kovalycsik M. Design Space and PAT - Q8 ICH Draft Guidance on Pharmaceutical Development. AVP, Wyeth Research Vaccines R&D, Quality Operations.

Khare R. Three Romeos And A Juliet An Early Brush With Design Of Experiments. www.isixsigma.com. Accessed 10 March 2016.

Burnham R. How to Select Design of Experiments Software. www.sixsigma.com. Accessed 10 March 2016.

Statistical Optimization of Pharmaceutical Formulations by P.K. Shiromani President Shirman Pharmaceutical Consulting.

ICH Quality Implementation working group. point to consider, ICH endorsed guide for ICH Q8/Q9/Q10 implementation. 2011

Yu LX, Amidon G, Khan MA, Hoag SW, Polli J, Raju GK, et al. Understanding pharmaceutical Quality by design. AAPS Journal. 2014;16:771-83.

Sangshetti JN, Zaheer Z, Mahaparale PR, Chitlange SS. Quality by design (QbD) in pharmaceuticals, Unique Publication, Aurangabad, 1st edition; 2015: 20.


  • There are currently no refbacks.

Copyright (c) 2016 Pharmaceutical and Biological Evaluations

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Creative Commons License


© Copyright 2018 - Pharmaceutical and Biological Evaluations